298 related articles for article (PubMed ID: 1512327)
1. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
[TBL] [Abstract][Full Text] [Related]
2. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group.
Rapold HJ; de Bono D; Arnold AE; Arnout J; De Cock F; Collen D; Verstraete M
Circulation; 1992 Mar; 85(3):928-34. PubMed ID: 1537129
[TBL] [Abstract][Full Text] [Related]
3. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
Hsia J; Kleiman N; Aguirre F; Chaitman BR; Roberts R; Ross AM
J Am Coll Cardiol; 1992 Jul; 20(1):31-5. PubMed ID: 1607535
[TBL] [Abstract][Full Text] [Related]
4. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.
Bleich SD; Nichols TC; Schumacher RR; Cooke DH; Tate DA; Teichman SL
Am J Cardiol; 1990 Dec; 66(20):1412-7. PubMed ID: 2123602
[TBL] [Abstract][Full Text] [Related]
5. Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group.
Zeymer U; von Essen R; Tebbe U; Niederer W; Mäurer W; Vogt A; Neuhaus KL
Am J Cardiol; 1995 Nov; 76(14):997-1001. PubMed ID: 7484879
[TBL] [Abstract][Full Text] [Related]
6. Patency trials with reteplase (r-PA): what do they tell us?
Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
[TBL] [Abstract][Full Text] [Related]
7. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
GUSTO Angiographic Investigators
N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.
Vanderschueren S; Barrios L; Kerdsinchai P; Van den Heuvel P; Hermans L; Vrolix M; De Man F; Benit E; Muyldermans L; Collen D
Circulation; 1995 Oct; 92(8):2044-9. PubMed ID: 7554180
[TBL] [Abstract][Full Text] [Related]
9. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.
de Bono DP; Simoons ML; Tijssen J; Arnold AE; Betriu A; Burgersdijk C; López Bescos L; Mueller E; Pfisterer M; Van de Werf F
Br Heart J; 1992 Feb; 67(2):122-8. PubMed ID: 1540431
[TBL] [Abstract][Full Text] [Related]
10. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
[TBL] [Abstract][Full Text] [Related]
11. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction.
Purvis JA; McNeill AJ; Siddiqui RA; Roberts MJ; McClements BM; McEneaney D; Campbell NP; Khan MM; Webb SW; Wilson CM
J Am Coll Cardiol; 1994 Jan; 23(1):6-10. PubMed ID: 8277097
[TBL] [Abstract][Full Text] [Related]
13. Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
Anderson JL; Becker LC; Sorensen SG; Karagounis LA; Browne KF; Shah PK; Morris DC; Fintel DJ; Mueller HS; Ross AM
J Am Coll Cardiol; 1992 Oct; 20(4):753-66. PubMed ID: 1527286
[TBL] [Abstract][Full Text] [Related]
14. Enhanced myocardial salvage by maintenance of microvascular patency following initial thrombolysis with recombinant tissue plasminogen activator.
Longridge DJ; Follenfant MJ; Maxwell MP; Ford AJ; Hughes B
Cardiovasc Res; 1990 Sep; 24(9):697-706. PubMed ID: 2121357
[TBL] [Abstract][Full Text] [Related]
15. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
Neuhaus KL; von Essen R; Tebbe U; Vogt A; Roth M; Riess M; Niederer W; Forycki F; Wirtzfeld A; Maeurer W
J Am Coll Cardiol; 1992 Apr; 19(5):885-91. PubMed ID: 1552106
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1.
O'Connor CM; Meese R; Carney R; Smith J; Conn E; Burks J; Hartman C; Roark S; Shadoff N; Heard M
J Am Coll Cardiol; 1994 Jan; 23(1):11-8. PubMed ID: 8277068
[TBL] [Abstract][Full Text] [Related]
17. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
Becker RC; Cannon CP; Tracy RP; Thompson B; Bovill EG; Desvigne-Nickens P; Randall AM; Knatternud G; Braunwald E
Am Heart J; 1996 Mar; 131(3):421-33. PubMed ID: 8604620
[TBL] [Abstract][Full Text] [Related]
18. Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: a multicenter trial.
DeWood MA; Kurnik PB; Jolly MK; Jain AC; Khaja F; Gorfinkel HJ; Morris DL; Satler L; LittleJohn J
Clin Cardiol; 1993 Apr; 16(4):302-10. PubMed ID: 8458110
[TBL] [Abstract][Full Text] [Related]
19. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
[TBL] [Abstract][Full Text] [Related]
20. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study.
Vermeer F; Vahanian A; Fels PW; Besse P; Müller E; Van de Werf F; Fitzgerald D; Darius H; Puel J; Garrigou D; Simoons ML;
J Thromb Thrombolysis; 2000 Dec; 10(3):233-40. PubMed ID: 11122543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
